Taking advantage of what Amag Pharmaceuticals Inc. President and CEO Bill Heiden called a "significant growth opportunity," the company is acquiring anticoagulant reversal agent developer Perosphere Pharmaceuticals Inc. for $50 million up front and up to $365 million in potential milestone payments. Analysts lauded the intent of the deal, praising its potential to further diversify Amag's portfolio and complement its oral iron therapy, Feraheme (ferumoxytol). But differentiating the phase II candidate, ciraparantag, from already-approved reversal agents Praxbind (idarucizumab) and Andexxa (coagulation factor Xa [recombinant], inactivated-zhzo), will be key to the program's success, they said.